We are a late-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and inflammatory diseases with the goal of improving patient outcomes. Our lead product candidate, cadisegliatin (TTP399) , is a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated in a Phase 3 clinical trial as a potential oral adjunctive ther…
Revenue declined 100.0% YoY. The question is whether this is cyclical or a structural shift.
Negative free cash flow of -$25M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$37M
▼ -100.0% YoY
Net Income (TTM)
$2M
▼ -46.1% YoY
Op. Margin
-8.26%
ROIC
-4.21%
▲ +224.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$10M
▲ +0.2% YoY
Op. Cash Flow (TTM)
-$10M
▲ +0.2% YoY
Net Debt
-$98M
Net Cash Position
Cash & Equiv.
$98M
Continue Research